trial

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

NCTId NCT00412620
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 156 (actual)
Sponsored by Abbott Medical Devices
Primary completion 2007-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
156 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2006-12
Primary completion
2007-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ABT-925

Sponsors

Abbott Medical DevicesLead Sponsor

Investigators

1
Beatrice Rendenbach-Mueller, PhDStudy Director

Sites

18 total
Anaheim, United StatesCerritos, United StatesGarden Grove, United StatesPico Rivera, United StatesSan Diego, United StatesUpland, United StatesNorth Miami, United StatesAtlanta, United StatesAustin, United StatesAustin, United StatesBellaire, United StatesBuenos Aires, Argentina

Linked catalysts

1
An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exace — primary completion2007-10

Facts & assertions

4 sourced
Enrollment
156
Phase
PHASE2
Primary Completion Date
2007-10
Status
TERMINATED
relationships
The graph out of here
drug
ABT-925
drug
lead_sponsor
Abbott Medical Devices
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Beatrice Rendenbach-Mueller, PhD
person